Gabapentin
Product Images NDC 66116-358

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 66116-358). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

562aa1bb-figure-01 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 01)

FDA Label Image

562aa1bb-figure-02 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 02)

562aa1bb-figure-02 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 02)
The text represents a graph or chart showing the results of a study that compares the effectiveness of Gabapentin and the placebo in managing pain over a period of 8 weeks, comprised of a 4-week Dose Titration Period and a 4-week Fixed Dose Period. The pain scores are shown on the vertical axis, with the baseline and consecutive weeks indicated on the horizontal axis. Gabapentin appears to be significantly more effective than the placebo, as indicated by the asterisk and the p-value.*
FDA Label Image

562aa1bb-figure-03 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 03)

562aa1bb-figure-03 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 03)
This is a graph that shows the mean pain score over a 3-week dose titration period and a 4-week fixed dose period for a placebo group, and groups taking Gabapentin at 1800 mg/day and 2400 mg/day. The graph indicates that the groups taking Gabapentin experienced significantly less pain compared to the placebo group. The significance of the results is denoted by "**p <0.01".*
FDA Label Image

562aa1bb-figure-04 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 04)

562aa1bb-figure-04 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 04)
This text presents data on the percentage of responders at endpoint for two different studies involving a drug called GBP compared to a placebo (PBO) with different dosages. The symbols "*k" and "***" denote statistical significance levels at p<0.01 and p<0.001, respectively. The exact nature of the endpoint is not clear from the available text.*
FDA Label Image

562aa1bb-figure-05 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 05)

FDA Label Image

562aa1bb-figure-06 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 06)

FDA Label Image

562aa1bb-figure-07 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 07)

FDA Label Image

562aa1bb-figure-08 (6b3ca748 7172 4c53 B5ae 7e17dad918eb 08)

FDA Label Image

Gabapentin 300mg Capsules (6b3ca748 7172 4c53 B5ae 7e17dad918eb 09)

Gabapentin 300mg Capsules (6b3ca748 7172 4c53 B5ae 7e17dad918eb 09)
This text contains medication dosage instructions and some important information like lot number, expiration date, storage instructions, and contact details. It also mentions the name of the manufacturer and distributor. However, due to the presence of symbols, errors, and incomplete sentences, a useful description cannot be generated.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.